Search results for "Arid"

showing 10 items of 1382 documents

Enriched cereal bars are more effective in increasing plasma quercetin compared with quercetin from powder-filled hard capsules

2011

The flavonol quercetin, is one of the major flavonoids found in edible plants. The bioavailability of quercetin in humans may be influenced by the food matrix in which it is consumed as well as by its chemical and physical form. The objective of the present study was to investigate the biokinetics of quercetin from quercetin-enriched cereal bars and quercetin powder-filled hard capsules. In a randomised, single-blinded, diet-controlled cross-over study, six healthy women aged 22–28 years took a single oral dose of approximately 130 mg quercetin equivalents from either quercetin-enriched cereal bars (containing 93·3 % quercetin aglycone plus 6·7 % quercetin-4′-glucoside) or quercetin powder-…

AdultMedicine (miscellaneous)CapsulesPilot ProjectsDisaccharidesHigh-performance liquid chromatographyAntioxidantsSingle oral doseYoung Adultchemistry.chemical_compoundHumansIngestionSingle-Blind MethodFood scienceAntihypertensive AgentsIsorhamnetinCross-Over StudiesNutrition and DieteticsBioavailabilityKineticsTamarixetinAglyconechemistryBiochemistryDietary SupplementsFood FortifiedFast FoodsFemaleQuercetinPowdersEdible GrainQuercetinNutritive ValueBritish Journal of Nutrition
researchProduct

Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey.

2011

Purpose: To use the Hunter Outcome Survey, an international database, to assess the safety and effectiveness of enzyme replacement therapy with idursulfase in patients with Hunter syndrome who started treatment before 6 years of age. Methods: The study population included all patients enrolled in the Hunter Outcome Survey who started idursulfase infusions (0.5 mg/kg every other week) before 6 years of age and who had at least one follow-up examination recorded. Results: The study population included 124 patients, younger than 6 years, who had a mean age at start of idursulfase of 3.6 ± 1.6 years (mean ± SD). The mean duration of treatment was 22.9 ± 14.6 months. A total of 69 infusion-relat…

AdultPediatricsmedicine.medical_specialtyAdolescentDatabases FactualIdursulfaseUrineIduronate Sulfatasechemistry.chemical_compoundYoung AdultInternational databaseMedicineHumansEnzyme Replacement TherapyYoung adultChildInfusions IntravenousGenetics (clinical)GlycosaminoglycansMucopolysaccharidosis IICreatinineClinical Trials as Topicbusiness.industryData CollectionInfantHunter syndromeEnzyme replacement therapymedicine.diseaseTreatment OutcomechemistryChild PreschoolPopulation studybusinessmedicine.drugGenetics in medicine : official journal of the American College of Medical Genetics
researchProduct

Burden of disease in patients with Morquio A syndrome: results from an international patient-reported outcomes survey

2013

WOS: 000335253700001

AdultQuality of lifemedicine.medical_specialtyActivities of daily livingInternationalityAdolescentDiseaseShort staturechemistry.chemical_compoundWheelchairQuality of lifeElosulfase alfaMedicineHumansGenetics(clinical)Pharmacology (medical)ChildGenetics (clinical)FatigueMobilityMedicine(all)Pain measurementPatient-reported outcomesbusiness.industryData CollectionResearchMucopolysaccharidosis IVGeneral MedicineGaithumanitiesEQ-5D-5LchemistryWheelchairsJoint painPhysical therapymedicine.symptombusinessMorquio A syndromeOrphanet Journal of Rare Diseases
researchProduct

Scheie syndrome: enzyme replacement therapy does not prevent progression of cervical myelopathy due to spinal cord compression.

2009

Hurler-Scheie syndrome is caused by alpha-l-iduronidase deficiency. Enzyme replacement therapy (ERT) can improve physical capacity and reduces organomegaly. However, the effect on bradytrophic connective tissue is limited. As intravenously administered enzyme cannot cross the blood-brain barrier, the therapy of choice for the more severe Hurler syndrome is haematopoietic stem cell transplantation (HCT). In the more attenuated Scheie syndrome, neurological impairment is less severe; therefore, ERT may be appropriate to treat these patients. Information on long-term outcome in Scheie patients undergoing ERT is scarce. We report a 38-year-old female Scheie patient who has been on ERT for 8 yea…

Adultcongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyMucopolysaccharidosis IMyelopathyIduronidaseSpinal cord compressionMucopolysaccharidosis IGeneticsmedicineHumansEnzyme Replacement TherapyHurler syndromeGenetics (clinical)business.industryHematopoietic Stem Cell Transplantationnutritional and metabolic diseasesBrainEnzyme replacement therapymedicine.diseaseSpinal cordSurgeryTransplantationmedicine.anatomical_structureCervical VertebraeDisease ProgressionFemaleScheie syndromebusinessSpinal Cord CompressionJournal of inherited metabolic disease
researchProduct

Multi-domain impact of elosufase alfa in Morquio A syndrome in the pivotal phase III trial

2015

Objective: To report and discuss the multi-domain impact of elosulfase alfa, with focus on tertiary and composite endpoints, in the 24-week, randomized, double-blind, placebo-controlled phase 3 trial in patients with Morquio A syndrome (mucopolysaccharidosis IVA). Methods: Patients with Morquio A syndrome >= 5 aged years were randomized 1:1:1 to elosulfase alfa 2.0 mg/kg/week (qw; N = 58), elosulfase alfa 2.0 mg/kg/every other week (qow; N = 59), or placebo (N = 59) for 24 weeks. Primary and secondary efficacy measures were 6-minute walk test (6MWT; primary), 3-minute stair climb test (3-MSCT) and urinary keratan sulfate (KS). Safety was also evaluated. Tertiary efficacy measures included r…

Adultmedicine.medical_specialtyAdolescentIdursulfaseMucopolysaccharidosisEndocrinology Diabetes and MetabolismPlaceboBiochemistrylaw.inventionYoung Adultchemistry.chemical_compoundEndocrinologyDouble-Blind MethodRandomized controlled trialElosulfase alfalawSurveys and QuestionnairesInternal medicineActivities of Daily LivingmedicineGeneticsHumansEnzyme Replacement TherapyRespiratory functionYoung adultChildMolecular Biologybusiness.industryMucopolysaccharidosis IVMaximal Voluntary VentilationMiddle Agedmedicine.diseaseBody HeightChondroitinsulfatasesRespiratory Function TestsTreatment OutcomechemistryChild PreschoolPhysical therapyPopulation studybusinessmedicine.drugMolecular genetics and metabolism
researchProduct

(Partial) loss of BAF250a (ARID1A) in rectovaginal deep-infiltrating endometriosis, endometriomas and involved pelvic sentinel lymph nodes

2015

study hypothesis: Loss of protein BAF250a (ARID1A) expression is present in women with rectovaginal deep-infiltrating endometriosis (DIE) and endometriosis affecting the pelvic sentinel lymph nodes (PSLN). study finding: Partial loss of protein BAF250a was found in some of our patient samples, comprising all endometriosis entities, including rectovaginal DIE and endometriosis affecting the PSLN. what is known already: Loss of BAF250a (BRG-associated factor 250a)/ARIDIA (AT-rich interactive domain 1A) protein expression was identified among endometriosis-associated ovarian carcinomas and ovarian endometriosis, and this phenomenonwas described as a possible early event in the transformation o…

Adultmedicine.medical_specialtyBAF250a human proteinEmbryologyARID1APelvic sentinel lymph nodePopulationEndometriosisEndometriosisDeep-infiltrating endometriosiEndometriumGastroenterologyMalignant transformation03 medical and health sciencesEndometriumYoung Adult0302 clinical medicineGeneticInternal medicineGeneticsmedicinePTENHumanseducationMolecular BiologyCancerOvarian Neoplasmseducation.field_of_study030219 obstetrics & reproductive medicinebiologyCancerNuclear ProteinsObstetrics and GynecologyCell BiologyMiddle Agedmedicine.diseaseImmunohistochemistryARID1ADNA-Binding Proteinsmedicine.anatomical_structureReproductive Medicine030220 oncology & carcinogenesisOvarian Endometriosisbiology.proteinFemaleSentinel Lymph NodeTranscription FactorsDevelopmental Biology
researchProduct

CARDIAC PUNCTURE OF FETUS WITH HURLER'S DISEASE AVOIDING ABORTION OF UNAFFECTED CO-TWIN

1978

Adultmedicine.medical_specialtyFetal ResorptionMucopolysaccharidosis IFetal heartPuncturesDiseaseAbortionIduronidaseFetal HeartPregnancyPrenatal DiagnosisDiseases in TwinsHumansMedicineFetal DeathGlucuronidaseGlycosaminoglycansFetusPregnancyFetal deathbusiness.industryObstetricsInfant NewbornFollow up studiesInfantFetal ResorptionGeneral MedicineFibroblastsAmniotic Fluidbeta-Galactosidasemedicine.diseaseAnesthesiaFemalebusinessFollow-Up StudiesThe Lancet
researchProduct

Development and testing of new screening method for keratan sulfate in mucopolysaccharidosis IVA.

2004

Mucopolysaccharidosis IVA (MPS IVA), a progressive lysosomal storage disease, causes skeletal dysplasia through excessive storage of keratan sulfate (KS). We developed an ELISA-sandwich assay that used a MAb specific to KS. Forty-five blood and 59 urine specimens from MPS IVA patients (ages 1–65 y) were analyzed to determine whether KS concentration is a suitable marker for early diagnosis and longitudinal assessment of disease severity. Blood specimens were obtained from patients categorized as phenotypically severe (n = 36) and milder (n = 9). Urine specimens were also analyzed from patients categorized as severe (n = 56) and milder (n = 12), respectively. Blood KS levels (101–1525 ng/mL)…

Adultmedicine.medical_specialtyPathologyAdolescentMucopolysaccharidosisStatistics as TopicEnzyme-Linked Immunosorbent AssayUrineGastroenterologyMucopolysaccharidosis Type IVAExcretionDiagnosis Differentialchemistry.chemical_compoundInternal medicinemedicineLysosomal storage diseaseHumansGenetic TestingChildAgedGlycosaminoglycansCreatininebusiness.industryInfantMucopolysaccharidosis IVReproducibility of ResultsMiddle Agedmedicine.diseasechemistryDysplasiaKeratan SulfateChild PreschoolPediatrics Perinatology and Child HealthMucopolysaccharidosis IVsense organsbusinessBiomarkersPediatric research
researchProduct

Column aerosol characterization in a semi‐arid region around Marrakech during the WATERMED 2003 campaign

2008

In the framework of the WATERMED (WATer use efficiency in natural vegetation and agricultural areas by Remote sensing in the MEDiterranean basin) project, an experimental field campaign was carried out in a semi‐arid region near Marrakech, Morocco, during March 2003. This work focused on the columnar aerosol characterization from spectroradiometric and photometric measurements of direct solar irradiance and sky radiance at ground level. The results show a high dependence of the aerosol optical properties on the air masses present in the area. Two periods with different aerosol loads were observed in the campaign. In the first, Atlantic‐origin aerosols showed a marine particle accumulation m…

AerosolsTeledeteccióRadiació solarMeteorologyIrradianceVegetationAtmospheric sciencesSolar irradianceAridAerosolAltitudeRadianceGeneral Earth and Planetary SciencesEnvironmental scienceTurbidityInternational Journal of Remote Sensing
researchProduct

Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help.

2007

Liver or lung metastases usually relapse under chemotherapy. Such life-threatening condition urgently needs new, systemic anticancer compounds, with original and efficient mechanisms of action. In B16 melanoma mice treated with cyclophosphamide, D'Agostini et al. [D'Agostini, C., Pica, F., Febbraro, G., Grelli, S., Chiavaroli, C., Garaci, E., 2005. Antitumour effect of OM-174 and Cyclophosphamide on murine B16 melanoma in different experimental conditions. Int. Immunopharmacol. 5, 1205-1212.] recently found that OM-174, a chemically defined Toll-like receptor(TLR)2/4 agonist, reduces tumor progression and prolongs survival. Here we review 149 articles concerning molecular mechanisms of TLR2…

AgonistLipopolysaccharidesCyclophosphamidemedicine.drug_classmedicine.medical_treatmentNitric Oxide Synthase Type IIAntineoplastic AgentsApoptosisNitric oxidechemistry.chemical_compoundRecurrenceNeoplasmsMedicineAnimalsHumansPharmacologyChemotherapybusiness.industryTumor Necrosis Factor-alphaCancerDendritic Cellsmedicine.diseaseNeoadjuvant TherapyToll-Like Receptor 2Interleukin-10Toll-Like Receptor 4TLR2Lipid ATreatment OutcomechemistryTumor progressionChemotherapy AdjuvantDrug Resistance NeoplasmEnzyme InductionImmunologyCancer researchBCG VaccineTumor necrosis factor alphaImmunotherapybusinessmedicine.drugSignal TransductionT-Lymphocytes CytotoxicEuropean journal of pharmacology
researchProduct